Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus ROCEPHIN.
ANSPOR vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic